|1.||Nehmé, Benjamin: 1 article (02/2009)|
|2.||Abed, Yacine: 1 article (02/2009)|
|3.||Baz, Mariana: 1 article (02/2009)|
|4.||Boivin, Guy: 1 article (02/2009)|
|5.||Gubareva, Larisa V: 1 article (03/2006)|
|6.||Ison, Michael G: 1 article (03/2006)|
|7.||Hayden, Frederick G: 1 article (03/2006)|
|8.||Mishin, Vasiliy P: 1 article (03/2006)|
|9.||Braciale, Thomas J: 1 article (03/2006)|
02/01/2009 - "A-322278 decreased mortality rates and lung virus titers significantly more than oseltamivir in mice infected with the NA H274Y mutant when therapy was started 4 h before or even 48 h after infection."
03/15/2006 - "Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection."
03/15/2006 - "We developed an immunocompromised murine model of influenza virus infection and demonstrated comparable efficacy of oral oseltamivir and A-322278 (both given at dosages of 10 mg/kg/day) in reducing viral replication, decreasing weight loss, and prolonging survival. "
|2.||Weight Loss (Weight Reduction)
|3.||Human Influenza (Influenza)